We are live on ! Find out more
HAE icon

Haemonetics

192 hedge funds and large institutions have $1.78B invested in Haemonetics in 2014 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 66 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 66

3% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 35

1.6% less ownership

Funds ownership: 107.02%105.42% (-1.6%)

2% less funds holding

Funds holding: 196192 (-4)

23% less capital invested

Capital invested by funds: $2.32B → $1.78B (-$540M)

70% less call options, than puts

Call options by funds: $411K | Put options by funds: $1.38M

Holders
192
Holders Change
-4
Holders Change %
-2.04%
% of All Funds
5.53%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
34
Increased
66
Reduced
66
Closed
35
Calls
$411K
Puts
$1.38M
Net Calls
-$968K
Net Calls Change
-$968K

HAE Hedge Fund Activity: Q1 2014 in Review

192 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2014, worth a combined $1.78B — down 23% from $2.32B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of HAE and 34 opened new positions — a net loss of 1 holder — while 66 trimmed existing stakes and 66 added.

The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $79.7M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $106M sold.

  • 192 institutional investors held Haemonetics (HAE) as of Q1 2014, down from 196 in Q4 2013.
  • Funds reported $1.78B of Haemonetics stock for Q1 2014, down 23% quarter-over-quarter.
  • 34 funds opened new Haemonetics positions in Q1 2014 and 35 closed out, a net change of -1 holder.
  • The largest Haemonetics buyer in Q1 2014 was Barrow, Hanley, Mewhinney & Strauss, an estimated $79.7M added.
  • The largest Haemonetics seller in Q1 2014 was TimesSquare Capital Management, an estimated $106M sold.

Based on aggregated 13F filings for Q1 2014.